Jastorff A, Gymnopoulou E, Salas J, Merrall E, et al. Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial. Vaccine 2024;43.
PMID: 39536455